Trump Just Opened Up A $400 BILLION Market (Get In Now)?
Summary
Felix outlines a comprehensive thesis on the emerging market for psychedelic-assisted therapy, driven by a 2024 executive order and the involvement of figures like RFK Jr. He uses Johnson & Johnson’s drug Spravato, which generates nearly $2 billion in annual revenue, as a 'proof of pudding' that insurance companies will pay for these treatments and that high demand exists among the 85 million people globally with treatment-resistant depression. Felix posits that the next wave of growth will come from smaller, pre-revenue biotech companies where a single successful drug could result in 10x returns.
However, Felix emphasizes that these are 'calculated speculations' rather than traditional investments. He recommends a diversified approach, spreading a small portfolio allocation of 1-3% across multiple players in the sector to mitigate the high risks associated with FDA approvals, clinical trial failures, and potential share dilution. He advises investors to focus on the 'catalyst calendar'—specifically pending FDA approvals in 2026 and 2027—and to be prepared to take profits rather than holding indefinitely, as innovation stocks often experience extreme volatility and long development cycles.
Mentioned Stocks
Reasoning: Felix used JNJ as proof of concept for the psychedelic market, noting their drug Spravato earns $2 billion annually. He sold his position for a 40% profit because JNJ is too large for this drug to significantly drive the stock price further compared to smaller firms.
Reasoning: Felix identifies Compass Pathways as the furthest along in development with its drug COMP360. He highlights that it has completed Phase 3 trials and could see FDA approval by 2026 or 2027, potentially leading to a 5-10 billion dollar valuation if it matches even half of JNJ's success.
Reasoning: Felix describes ATAI as a 'platform bet' backed by Peter Thiel. It is more diversified than its peers with five drugs in clinical development and holds a stake in Compass Pathways, offering a safer way to gain exposure to the broader category.
Reasoning: Felix views GH Research as a technology play. Their treatment requires only a 30-minute session compared to the 6-8 hours for competitors, which Felix argues will lead to much faster commercial adoption and clinic efficiency.